Jonathan Honey

Mr. Jonathan Honey

University of Cambridge
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
OBOeystein Roed Brekk
Oeystein Roed Brekk
JHJonathan Honey
Jonathan Honey
SLSeungil Lee
Seungil Lee
PHPenelope J. Hallett
Penelope J. Hallett
OIOle Isacson
Ole Isacson
Significance: Recently, the field of Parkinson’s disease biology has shifted attention away from pure proteinotoxic hypotheses to emphasize primary cellular insults, including glycolipid disturbances. In this work, dopaminergic neurons in the Parkinson’s disease-vulnerable region of substantia nigra were found to accumulate neutral lipids, whereas in the same tissues, astrocytes have reduced lipid content, and resident microglia (a form of brain macrophage) show overall accumulation of lipids associated with inflammation. These changes were reproduced experimentally by blocking a specific lysosomal hydrolase in mice, generating a glycolipid accumulation in the animals. Based on these findings, it is reasonable to propose that restoring lipid homeostasis between neurons, astrocytes, and microglia could potentially influence PD pathogenesis and disease progression.

3 March 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
CPCaroline Pearce
Caroline Pearce
JHJonathan Honey
Jonathan Honey
RLRoberta Lovick
Roberta Lovick
NCNicola Zapiain Creamer
Nicola Zapiain Creamer
CHClaire Henry
Claire Henry
SBStephen Barclay
Stephen Barclay
Objectives To investigate the experiences and views of practitioners in the UK and Ireland concerning changes in bereavement care during the COVID-19 pandemic. Design Online survey using a snowball sampling approach. Setting Practitioners working in hospitals, hospices, care homes and community settings across the UK and Ireland. Participants Health and social care professionals involved in bereavement support. Interventions Brief online survey distributed widely across health and social care organisations. Results 805 respondents working in hospice, community, and hospital settings across the UK and Ireland completed the survey between 3 August and 4 September 2020. Changes to bereavement care practice were reported in: the use of telephone, video and other forms of remote support (90%); supporting people bereaved from non-COVID conditions (76%), from COVID-19 (65%) and people bereaved before the pandemic (61%); funeral arrangements (61%); identifying bereaved people who might need support (56%); managing complex forms of grief (48%) and access to specialist services (41%). Free-text responses demonstrated the complexities and scale of the impact on health and social care services, practitioners and their relationships with bereaved families, and on bereaved people. Conclusions The pandemic has created major challenges for the support of bereaved people: increased needs for bereavement care, transition to remote forms of support and the stresses experienced by practitioners, among others. The extent to which services are able to adapt, meet the escalating level of need and help to prevent a ‘tsunami of grief’ remains to be seen. The pandemic has highlighted the need for bereavement care to be considered an integral part of health and social care provision.

16 August 2021 in Biosensors
Verified
Journal Article
Open access
PDF file
SMShan Mian
Shan Mian
JHJonathan Honey
Jonathan Honey
ACAlejandro Carnicer-Lombarte
Alejandro Carnicer-Lombarte
DBDamiano Giuseppe Barone
Damiano Giuseppe Barone
Brain–computer interfaces (BCI) are reliant on the interface between electrodes and neurons to function. The foreign body reaction (FBR) that occurs in response to electrodes in the brain alters this interface and may pollute detected signals, ultimately impeding BCI function. The size of the FBR is influenced by several key factors explored in this review; namely, (a) the size of the animal tested, (b) anatomical location of the BCI, (c) the electrode morphology and coating, (d) the mechanics of electrode insertion, and (e) pharmacological modification (e.g., drug eluting electrodes). Trialing methods to reduce FBR in vivo, particularly in large models, is important to enable further translation in humans, and we systematically reviewed the literature to this effect. The OVID, MEDLINE, EMBASE, SCOPUS and Scholar databases were searched. Compiled results were analysed qualitatively. Out of 8388 yielded articles, 13 were included for analysis, with most excluded studies experimenting on murine models. Cats, rabbits, and a variety of breeds of minipig/marmoset were trialed. On average, over 30% reduction in inflammatory cells of FBR on post mortem histology was noted across intervention groups. Similar strategies to those used in rodent models, including tip modification and flexible and sinusoidal electrode configurations, all produced good effects in histology; however, a notable absence of trials examining the effect on BCI end-function was noted. Future studies should assess whether the reduction in FBR correlates to an improvement in the functional effect of the intended BCI.

23 November 2023 in Arthritis Care & Research
Verified
Journal Article
Open access
HMHannah R. Mudge
Hannah R. Mudge
JHJonathan Honey
Jonathan Honey
STSara Tachoukaft
Sara Tachoukaft
SHSamantha L. Hider
Samantha L. Hider
KMKayleigh J. Mason
Kayleigh J. Mason
CBClaire Burton
Claire Burton
Objective: Musculoskeletal symptoms are commonly reported following acute COVID‐19. It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seeks to identify evidence for an association between acute COVID‐19 and subsequent iRMD diagnosis.Methods: A rapid review of the literature using a systematic search of Medline, EMBASE and two COVID‐19 databases was undertaken until August 2022. Case studies, case series, cross‐sectional, case‐control, and cohort studies reporting patients with an incident iRMD following COVID‐19 were included. Title and abstract screening were conducted by one reviewer and full text screening by two reviewers. Data extraction and quality appraisal were by one reviewer, with a second verifying. Study‐type specific critical appraisal tools were used.Results: Results were narratively synthesized. A total of 80 studies were included (69 case reports, 10 case series and 1 cross‐sectional study). Commonly reported iRMDs were “reactive arthropathies” (n = 47), “inflammatory arthropathies unspecified” (n = 18), rheumatoid arthritis (n = 12) and systemic lupus erythematosus (n = 11). The cross‐sectional study reported 37% of those with COVID‐19 developed “post COVID arthritis.” Time from diagnosis of COVID‐19 to iRMD presentation ranged from 0 to 120 days. Several mechanisms were proposed to explain the association between COVID‐19 and iRMD development: autoimmune processes, aberrant inflammatory responses, colonization of joint spaces, direct damage from the severe acute respiratory syndrome coronavirus 2 virus and genetic predisposition.Conclusion: The level of evidence of the studies included in this review was low and the quality generally poor. Prospective observational studies are required to confirm associations and likely impact of post COVID‐19 iRMDs at a population level.

30 May 2022 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
JHJonathan Honey
Jonathan Honey
HMHannah Rebecca Mudge
Hannah Rebecca Mudge